Skip to main content

Table 2 Blocking of [ 18 F]afatinib uptake in HCC827 xenografts

From: A comparative PET imaging study with the reversible and irreversible EGFR tyrosine kinase inhibitors [11C]erlotinib and [18F]afatinib in lung cancer-bearing mice

Added dose of afatinib (ng) Tumor-to-background ratio
0 2.3 ± 0.4*
100 1.1 ± 0.4
300 1.0 ± 0.3
1,000 0.9 ± 0.2
3,000 0.9 ± 0.3
  1. Tumor-to-background ratio after a bolus injection of [18F]afatinib with added isotopically unmodified afatinib. Ratios determined in the last frame of the scans (90 to 120 min) and averaged over three animals.*Tumor-to-background is statistically significant (P < 0.05, Student’s t-test for paired data). HCC827 xenografts harbor an exon 19 deleted variant of EGFR.